Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)‐Resistant CML Lines While Circumventing Pharmacokinetic Liabilities
暂无分享，去创建一个
P. Lai | M. Deininger | T. O'hare | P. Gunning | A. Eiring | N. Vellore | W. Heaton | Ahmed M. Ali | Ami B Patel | D. Ball | R. F. Gómez-Biagi | Andrew E. Shouksmith | D. Rosa | J. Park | Elvin D. de Araujo | David A. Rosa | Rodolfo F. Gómez-Biagi